This global opinion, published in Current Medical Research and Opinion, declares the consensus findings of The International Aromatase Inhibitor (AI) Expert Panel, composed of 24 breast cancer clinicians from Europe, the US, Australia, China and Brazil, who agreed that AIs should be prescribed as the preferred therapy in this patient setting.
The panel reviewed data from major early breast cancer aromatase treatment trials with the aim of providing a “rational interpretation of the impact of these data on current practice and to highlight areas where further investigation is needed.” The panel’s findings reaffirm current guidelines regarding the use of aromatase inhibitors, such as AstraZeneca’s Arimidex.
“This guidance helps to clarify considerations for use of AIs in everyday practice. These data provide the evidence that support using an aromatase inhibitor at the earliest opportunity,” commented panel member Dr Aman Buzdar, professor of medicine for the department of breast medical oncology at The University of Texas MD Anderson Cancer Center in Houston.